Role of P53 Isoforms and Aggregations in Cancer

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 Jul 2

PMID 27368003

Citations 37

Authors

Sejin Kim

Seong Soo A An

Affiliations

Soon will be listed here.

Abstract

p53 is a master regulatory protein that is involved in diverse cellular metabolic processes such as apoptosis, DNA repair, and cell cycle arrest. The protective function of p53 (in its homotetrameric form) as a tumor suppressor is lost in more than 50% of human cancers.Despite considerable experimental evidence suggesting the presence of multiple p53 states, it has been difficult to correlate the status of p53 with cancer response to treatments and clinical outcomes, which suggest the importance of complex but essential p53 regulatory pathways.Recent studies have indicated that the expression pattern of p53 isoforms may play a crucial role in regulating normal and cancer cell fates in response to diverse stresses. The human TP53 gene encodes at least 12 p53 isoforms, which are produced in normal tissue through alternative initiation of translation, usage of alternative promoters, and alternative splicing. Furthermore, some researchers have suggested that the formation of mutant p53 aggregates may be associated with cancer pathogenesis due to loss-of function (LoF), dominant-negative (DN), and gain-of function (GoF) effects.As different isoforms or the aggregation state of p53 may influence tumorigenesis, this review aims to examine the correlation of p53 isoforms and aggregation with cancer.

Citing Articles

Multimer Detection System: A Universal Assay System for Differentiating Protein Oligomers from Monomers.

Jamerlan A, Shim K, Sharma N, An S Int J Mol Sci. 2025; 26(3).

PMID: 39940966 PMC: 11818661. DOI: 10.3390/ijms26031199.

Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.

Sobczynska-Konefal A, Jasek M, Karabon L, Jaskula E Biomark Res. 2024; 12(1):162.

PMID: 39732734 PMC: 11682641. DOI: 10.1186/s40364-024-00710-w.

Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.

Ikliptikawati D, Makiyama K, Hazawa M, Wong R Int J Mol Sci. 2024; 25(13).

PMID: 39000572 PMC: 11242911. DOI: 10.3390/ijms25137465.

Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated "Omics" Approaches to Explore Measurable Metrics.

Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis A, Soundararajan R Cancers (Basel). 2023; 15(17).

PMID: 37686633 PMC: 10486655. DOI: 10.3390/cancers15174357.

Predictive Factors for Pediatric Craniopharyngioma Recurrence: An Extensive Narrative Review.

Serbis A, Tsinopoulou V, Papadopoulou A, Kolanis S, Sakellari E, Margaritis K Diagnostics (Basel). 2023; 13(9).

PMID: 37174978 PMC: 10177772. DOI: 10.3390/diagnostics13091588.

References

Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev D, Segal D . Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One. 2010; 5(11):e13863. PMC: 2978097. DOI: 10.1371/journal.pone.0013863. View

Wolf D, Harris N, Goldfinger N, Rotter V . Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol Cell Biol. 1985; 5(1):127-32. PMC: 366686. DOI: 10.1128/mcb.5.1.127-132.1985. View

Lane D, CRAWFORD L . T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979; 278(5701):261-3. DOI: 10.1038/278261a0. View

Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P . Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol. 2013; 42(4):1181-8. DOI: 10.3892/ijo.2013.1818. View

Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V . Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ. 2011; 19(5):816-26. PMC: 3321620. DOI: 10.1038/cdd.2011.152. View

Aguzzi A, Rajendran L . The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron. 2010; 64(6):783-90. DOI: 10.1016/j.neuron.2009.12.016. View

Brown C, Lain S, Verma C, Fersht A, Lane D . Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009; 9(12):862-73. DOI: 10.1038/nrc2763. View

Boldrup L, Bourdon J, Coates P, Sjostrom B, Nylander K . Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer. 2007; 43(3):617-23. PMC: 3523263. DOI: 10.1016/j.ejca.2006.10.019. View

Courtois S, Verhaegh G, North S, Lassus P, Hibner U, Oren M . DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene. 2002; 21(44):6722-8. DOI: 10.1038/sj.onc.1205874. View

10.

Olivier M, Hollstein M, Hainaut P . TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2(1):a001008. PMC: 2827900. DOI: 10.1101/cshperspect.a001008. View

11.

Xu J, Reumers J, Couceiro J, De Smet F, Gallardo R, Rudyak S . Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011; 7(5):285-95. DOI: 10.1038/nchembio.546. View

12.

Khoury M, Marcel V, Fernandes K, Diot A, Lane D, Bourdon J . Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Methods Mol Biol. 2012; 962:1-14. DOI: 10.1007/978-1-62703-236-0_1. View

13.

Lasagna-Reeves C, Clos A, Castillo-Carranza D, Sengupta U, Guerrero-Munoz M, Kelly B . Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem Biophys Res Commun. 2012; 430(3):963-8. DOI: 10.1016/j.bbrc.2012.11.130. View

14.

Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S . Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984; 3(13):3257-62. PMC: 557846. DOI: 10.1002/j.1460-2075.1984.tb02287.x. View

15.

Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I . Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 2011; 105(10):1593-9. PMC: 3242533. DOI: 10.1038/bjc.2011.433. View

16.

Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A . The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J. 2008; 94(9):3635-46. PMC: 2292390. DOI: 10.1529/biophysj.107.122283. View

17.

Lee A, Galea C, DiGiammarino E, Jun B, Murti G, Ribeiro R . Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant. J Mol Biol. 2003; 327(3):699-709. DOI: 10.1016/s0022-2836(03)00175-x. View

18.

Forget K, Tremblay G, Roucou X . p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53. PLoS One. 2013; 8(7):e69242. PMC: 3700952. DOI: 10.1371/journal.pone.0069242. View

19.

Meek D, Anderson C . Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol. 2010; 1(6):a000950. PMC: 2882125. DOI: 10.1101/cshperspect.a000950. View

20.

Bourdon J, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas D . p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005; 19(18):2122-37. PMC: 1221884. DOI: 10.1101/gad.1339905. View